Exact Sciences(US:EXAS)2025-11-03 22:00Financial Performance - Total revenue in 3Q25 reached $851 million, a 20% year-over-year increase[5] - Adjusted EBITDA in 3Q25 was $135 million, up 37% year-over-year[5] - Core revenue grew by 20% in 3Q25[7] - Screening revenue increased by 22% from $545 million in 3Q24 to $666 million in 3Q25[8] - Precision Oncology core revenue increased by 12% from $163 million in 3Q24 to $183 million in 3Q25[8] - Adjusted EBITDA margin improved to 16% in 3Q25, a 200 basis points increase from 14% in 3Q24[11] Guidance Update - Total revenue guidance for 2025 was updated to $3220-$3235 billion, an increase of $78 million at the midpoint[13] - Screening revenue guidance for 2025 was updated to $2510-$2520 billion, an increase of $60 million at the midpoint[13] - Precision Oncology revenue guidance for 2025 was updated to $710-$715 million, an increase of $18 million at the midpoint[13] - Adjusted EBITDA guidance for 2025 was updated to $470-$480 million, an increase of $10 million at the midpoint[13]